What Researchers Did
This paper reviewed primary data from clinical trials conducted by the Radiation Therapy Oncology Group (RTOG) for patients with uterine cervical cancer.
What They Found
The review found that Phase III clinical trials by the RTOG did not show a local control or survival advantage for hyperbaric oxygen, split-course radiotherapy, hypoxic cell sensitization, or neutron radiotherapy in cervical cancer patients. However, acceptable toxicity and efficacy were observed in Phase II studies evaluating twice-daily irradiation and chemo-sensitization. Positive Phase III trial results were reported for prophylactic paraaortic irradiation (RTOG 79-20) and concurrent chemotherapy (RTOG 90-01).
What This Means for Canadian Patients
For Canadian patients with cervical cancer, this review suggests that hyperbaric oxygen therapy, as evaluated in these RTOG Phase III trials, did not improve local control or survival. Patients and clinicians should consider other established treatment approaches, such as concurrent chemotherapy and prophylactic paraaortic irradiation, which showed positive results in specific RTOG trials. This information helps guide treatment discussions and decisions regarding the efficacy of various adjunctive therapies.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This paper is a review of trials conducted over 25 years ago, and the findings regarding hyperbaric oxygen are based on older study designs and patient populations.